SCHEDULE 13G/A: Gilead Sciences Discloses 3.9% Stake in Newly Renamed Kalaris Therapeutics Following Merger

Gilead Sciences, Inc. has filed an amended Schedule 13G, disclosing a 3.9% beneficial ownership stake in Kalaris Therapeutics, Inc., which recently completed a merger and changed its name and ticker symbol.

Summary

• Gilead Sciences, Inc. beneficially owns 723,273 shares of Kalaris Therapeutics, Inc. common stock.
• This represents 3.9% of the class, based on 18,702,413 shares outstanding immediately following the merger's effective time.
• The filing is an Amendment No. 2 to Schedule 13G, with the event date being March 18, 2025.
• Kalaris Therapeutics, Inc. is the new name of the Issuer, effective immediately following the merger.
• The merger involved the Issuer, Aurora Merger Sub, Inc., and Kalaris Tx, Inc. (formerly Kalaris Therapeutics, Inc.), with Merger Sub merging into Legacy Kalaris.
• The company's common stock ticker symbol changed from "ALVR" to "KLRS" on March 19, 2025, and it moved from The Nasdaq Capital Market to The Nasdaq Global Market.
• The CUSIP number for the common stock is now 482929106.

Sentiment

Score: 5

Explanation: The document is a standard regulatory disclosure of beneficial ownership following a corporate merger and name change. It contains factual information without expressing positive or negative sentiment regarding the company's performance or outlook.

Positives

• Completion of the merger, leading to the formation of the new Kalaris Therapeutics, Inc.
• Listing on The Nasdaq Global Market, potentially indicating increased visibility and liquidity compared to The Nasdaq Capital Market.

Future Outlook

The document does not provide specific forward-looking statements or guidance beyond the details of the completed merger and subsequent corporate changes.

Industry Context

This filing reflects a routine disclosure of a significant ownership stake by a major pharmaceutical company, Gilead Sciences, in a newly structured biotechnology firm, Kalaris Therapeutics, following a merger. Such disclosures are common in the life sciences sector, particularly after corporate restructuring events like mergers, as larger entities often hold strategic investments in smaller, innovative companies.

Comparison to Industry Standards

• This Schedule 13G filing is a standard regulatory disclosure for beneficial ownership exceeding 5% (or in this case, an amendment to a previous filing, even if below 5% now, due to changes in the issuer's structure).
• The 3.9% stake held by Gilead Sciences, a prominent biopharmaceutical company, in Kalaris Therapeutics, a company focused on therapeutics, is a common type of strategic investment or legacy holding that can arise from prior collaborations, venture investments, or as a result of corporate transactions like mergers.
• While specific comparable companies or projects are not detailed in this filing, it aligns with industry practices where larger pharmaceutical companies maintain equity positions in smaller biotech firms, often to foster partnerships or as a result of spin-offs or acquisitions.

Stakeholder Impact

• Shareholders of Kalaris Therapeutics, Inc. (formerly ALVR) are impacted by the name change to Kalaris Therapeutics, Inc., the ticker symbol change to KLRS, and the move to The Nasdaq Global Market, which may affect stock visibility and trading.
• Gilead Sciences, Inc. shareholders are informed of their company's continued beneficial ownership stake in Kalaris Therapeutics, Inc.

Key Dates

Keywords

Kalaris Therapeutics, Gilead Sciences, Schedule 13G, Beneficial Ownership, Merger, Stock Ownership, SEC Filing, KLRS, ALVR, Nasdaq Global Market, Biotechnology, Pharmaceuticals